Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma (Q33580777)

28 July 2017

1 reference

title

Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma (English)

1 reference

28 July 2017

1 reference

1

C Blake Gilks

1 reference

28 July 2017

30 December 2009

1 reference

28 July 2017

1 reference

28 July 2017

2010

1 reference

28 July 2017

740968

1 reference

Creative Commons Attribution 3.0 Unported

28 July 2017

start time

1 January 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Ovarian carcinoma pathology and genetics: recent advances

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

Ovarian carcinoma subtypes are different diseases: implications for biomarker studies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

A limited panel of immunomarkers can reliably distinguish between clear cell and high-grade serous carcinoma of the ovary

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

Critical molecular abnormalities in high-grade serous carcinoma of the ovary

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

Interobserver and intraobserver variability of a two-tier system for grading ovarian serous carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

Synergy between PPARgamma ligands and platinum-based drugs in cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

c-KIT codon 816 mutation in a recurrent and metastatic dysgerminoma of a 14-year-old girl: case study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor).

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

Diverse tumorigenic pathways in ovarian serous carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

Spectrum of FOXL2 gene mutations in blepharophimosis-ptosis-epicanthus inversus (BPES) families demonstrates a genotype--phenotype correlation

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

The putative forkhead transcription factor FOXL2 is mutated in blepharophimosis/ptosis/epicanthus inversus syndrome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

Activating c-kit gene mutations in human germ cell tumors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

Synchronous endometrioid tumors of the ovary and endometrium. A clinicopathologic study of 22 cases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

Two pathogenetic types of endometrial carcinoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma.

21 June 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F740968

Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F740968

Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F740968

Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F740968

Assessment of Her-1, Her-2, And Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F740968

The human FOXL2 mutation database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F740968

Mutation ofFOXL2in Granulosa-Cell Tumors of the Ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F740968

Differences in tumor type in low-stage versus high-stage ovarian carcinomas

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

Mutations in the beta-catenin gene (CTNNB1) in endometrioid ovarian carcinomas.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2804051

Chromosome 12p abnormalities in dysgerminoma of the ovary: a FISH analysis

31 October 2018

1 reference

https://api.crossref.org/works/10.1155%2F2010%2F740968

Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential

21 January 2018

1 reference

12 December 2020

Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer

1 reference

12 December 2020

Grading ovarian serous carcinoma using a two-tier system

1 reference

12 December 2020

Synchronous endometrioid carcinomas of the uterine corpus and ovary: alterations in the beta-catenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis

1 reference

12 December 2020

Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications

1 reference

12 December 2020

Exploiting the DNA Repair Defect in BRCA Mutant Cells in the Design of New Therapeutic Strategies for Cancer

1 reference

12 December 2020

Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group

1 reference

12 December 2020

Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas

1 reference

12 December 2020

K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases

1 reference

12 December 2020

Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma

1 reference

12 December 2020

WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma

1 reference

12 December 2020

Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease

1 reference

12 December 2020

Identifiers

DOI

10.1155/2010/740968

1 reference

28 July 2017

1 reference

28 July 2017

1 reference

PubMed ID

20069115